PDCD1 and non-small cell lung carcinoma: ICIs can activate T lymphocytes to secrete IFN- γ, to reduce local hypoxia and promote the normalization of tumor vessels, which demonstrates the synergistic effect of anti-PD-1/PD-L1 antibodies combined with antiangiogenic drugs and provides a theoretical basis for their combination in the treatment of NSCLC (37, 38).